secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2024-10-03T23:59:59+00:00
Accession:  0001193125-24-232306
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda amends bylaws with clarifications on special meetings, advance notice, and director nominations
--------------------------------------------------------------------------------

- Board approved amended bylaws effective October 2, 2024; changes include clarifying special meeting scope to agenda topics only.
- Advance notice provisions for shareholder nominations and proposals expanded with additional disclosure requirements.
- Adjournment process clarified for meetings relying on remote communication due to technical failure.
- Proxy solicitation requirements and director candidate standards spelled out more explicitly.
- Special board meetings may now be called by a majority of directors; officer definition narrowed to exclude non-officer title holders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524232306/0001193125-24-232306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524232306/d828148d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-232306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer